Crystal structure of arginase from Plasmodium falciparum and implications for L-arginine depletion in malarial infection .

The 2.15 A resolution crystal structure of arginase from Plasmodium falciparum, the parasite that causes cerebral malaria, is reported in complex with the boronic acid inhibitor 2(S)-amino-6-boronohexanoic acid (ABH) (K(d) = 11 microM). This is the first crystal structure of a parasitic arginase. Various protein constructs were explored to identify an optimally active enzyme form for inhibition and structural studies and to probe the structure and function of two polypeptide insertions unique to malarial arginase: a 74-residue low-complexity region contained in loop L2 and an 11-residue segment contained in loop L8. Structural studies indicate that the low-complexity region is largely disordered and is oriented away from the trimer interface; its deletion does not significantly compromise enzyme activity. The loop L8 insertion is located at the trimer interface and makes several intra- and intermolecular interactions important for enzyme function. In addition, we also demonstrate that arg- Plasmodium berghei sporozoites show significantly decreased liver infectivity in vivo. Therefore, inhibition of malarial arginase may serve as a possible candidate for antimalarial therapy against liver-stage infection, and ABH may serve as a lead for the development of inhibitors.

[1]  R. Titus,et al.  Local Suppression of T Cell Responses by Arginase-Induced L-Arginine Depletion in Nonhealing Leishmaniasis , 2009, PLoS neglected tropical diseases.

[2]  C. Wrenger,et al.  The activity of Plasmodium falciparum arginase is mediated by a novel inter‐monomer salt‐bridge between Glu295–Arg404 , 2009, The FEBS journal.

[3]  Joanne M. Morrisey,et al.  Host-parasite interactions revealed by Plasmodium falciparum metabolomics. , 2009, Cell host & microbe.

[4]  J. Weinberg,et al.  Arginine, nitric oxide, carbon monoxide, and endothelial function in severe malaria , 2008, Current opinion in infectious diseases.

[5]  A. Shoukas,et al.  Endothelial Arginase II: A Novel Target for the Treatment of Atherosclerosis , 2008, Circulation research.

[6]  S. Kappe,et al.  Malaria: progress, perils, and prospects for eradication. , 2008, The Journal of clinical investigation.

[7]  D. Conway,et al.  Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  R. Price,et al.  Impaired nitric oxide bioavailability and l-arginine–reversible endothelial dysfunction in adults with falciparum malaria , 2007, The Journal of experimental medicine.

[9]  K. Henrick,et al.  Inference of macromolecular assemblies from crystalline state. , 2007, Journal of molecular biology.

[10]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[11]  H. Algood,et al.  l-Arginine Availability Regulates Inducible Nitric Oxide Synthase-Dependent Host Defense against Helicobacter pylori , 2007, Infection and Immunity.

[12]  P. Rodriguez,et al.  Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[13]  E. Uribe,et al.  Mutational analysis of substrate recognition by human arginase type I − agmatinase activity of the N130D variant , 2006, The FEBS journal.

[14]  J. Frangos,et al.  Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria , 2006, Nature Medicine.

[15]  Mark A DePristo,et al.  On the abundance, amino acid composition, and evolutionary dynamics of low-complexity regions in proteins. , 2006, Gene.

[16]  S. Signoretti,et al.  Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. , 2005, Cancer research.

[17]  S. Hay,et al.  The global distribution of clinical episodes of Plasmodium falciparum malaria , 2005, Nature.

[18]  D. Christianson Arginase: structure, mechanism, and physiological role in male and female sexual arousal. , 2005, Accounts of chemical research.

[19]  J. Boucher,et al.  Inhibitor coordination interactions in the binuclear manganese cluster of arginase. , 2004, Biochemistry.

[20]  Fourie Joubert,et al.  Parasite-specific inserts in the bifunctional S-adenosylmethionine decarboxylase/ornithine decarboxylase of Plasmodium falciparum modulate catalytic activities and domain interactions. , 2004, The Biochemical journal.

[21]  L. Aravind,et al.  Plasmodium Biology Genomic Gleanings , 2003, Cell.

[22]  D. Christianson,et al.  Human Arginase II: Crystal Structure and Physiological Role in Male and Female Sexual Arousal†,‡ , 2003 .

[23]  Jonathan E. Allen,et al.  Genome sequence of the human malaria parasite Plasmodium falciparum , 2002, Nature.

[24]  A. Gobert,et al.  Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: A strategy for bacterial survival , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Alonso,et al.  Glu‐256 is a main structural determinant for oligomerisation of human arginase I , 2001, FEBS letters.

[26]  S. Morris,et al.  Expression, purification, and characterization of human type II arginase. , 2001, Archives of biochemistry and biophysics.

[27]  E. Pizzi,et al.  Low-complexity regions in Plasmodium falciparum proteins. , 2001, Genome research.

[28]  S. Cederbaum,et al.  Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. , 2000, Cancer research.

[29]  E N Baker,et al.  Crystal structures of Bacillus caldovelox arginase in complex with substrate and inhibitors reveal new insights into activation, inhibition and catalysis in the arginase superfamily. , 1999, Structure.

[30]  S. Cederbaum,et al.  Molecular basis of hyperargininemia: structure-function consequences of mutations in human liver arginase. , 1998, Molecular genetics and metabolism.

[31]  D. Christianson,et al.  Structure of a unique binuclear manganese cluster in arginase , 1996, Nature.

[32]  M. Modolell,et al.  Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow‐derived macrophages by TH 1 and TH 2 cytokines , 1995, European journal of immunology.

[33]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[34]  R. Archibald COLORIMETRIC DETERMINATION OF UREA , 1945 .

[35]  R. D. Walter,et al.  Structural metal dependency of the arginase from the human malaria parasite Plasmodium falciparum , 2005, Biological chemistry.

[36]  P. Stacpoole,et al.  Metabolic complications of severe malaria. , 2005, Current topics in microbiology and immunology.

[37]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination , 2022 .